The pharmacological treatment of pulmonary arterial hypertension

Pharmacological Reviews

Volumn 64, Issue 3, 2012, Pages 583-620

  Frumkin, Lyn R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMLODIPINE; BOSENTAN; DILTIAZEM; ILOPROST; NIFEDIPINE; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNIPROST;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOODSTREAM INFECTION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; EXERCISE; FLU LIKE SYNDROME; FLUSHING; FUNCTIONAL STATUS; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; JAUNDICE; JAW PAIN; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; NAUSEA; OVERALL SURVIVAL; PREGNANCY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG DISCOVERY; HUMANS; HYPERTENSION, PULMONARY; PULMONARY CIRCULATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84930477245     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.111.005587     Document Type: Article

References (266)

1. Abe K, Toba M, Alzoubi A, Koubsky K, Ito M, Ota H, Gairhe S, Gerthoffer WT, Fagan KA, McMurtry IF, et al. (2011) Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol 45:804-808.
2. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335:609-616.
3. Adcirca [U.S. package insert]. Eli Lilly and Co., Indianapolis, IN.
4. Actelion (2012) Actelion's macitentan meets primary endpoint in pivotal Phase III SERAPHIN outcome study in patients with pulmonary arterial hypertension 2012 Apr 30. Available at http://www.actelion.com/en/our-company/news-and-events/index.page?newsId_1607160.
5. Alp S, Skrygan M, Schmidt WE, and Bastian A (2006) Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm Pharmacol Ther 19:386-390.
6. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111-117.
7. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, et al. (2012) ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 30:93-99.
8. Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, and Crater GD (2009) Long-term survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol 36:2244-2249.
9. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, et al. (2010) Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137:376-387.
10. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, et al. (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425-434.
11. Baquero H, Soliz A, Neira F, Venegas ME, and Sola A (2006) Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117:1077-1083.
12. Barst RJ (2007) Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 8:95-109.
13. Barst RJ, Ertel SI, Beghetti M, and Ivy DD (2011a) Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 37:665-677.
14. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, and Rubin LJ (2006a) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28:1195-1203.
15. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, and Galié N (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54:S78-84.
16. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, and van Giersbergen PL (2003a) Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73:372-382.
17. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, et al. (2012) A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 125:324-334.
18. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N, and STRIDE-2 Study Group (2006b) Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47:2049-2056.
19. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, et al. (2004a) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169:441-447.
20. Barst RJ, Maislin G, and Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99:1197-1208.
21. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, et al. (2003b) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119-2125.
22. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, and Gaine S (2004b) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43:40S-47S.
23. Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza RL, Castro O, Naeije R, Sood N, Swerdlow PS, Hildesheim M, et al. (2010) Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol 149:426-435.
24. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galié N, and Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group (2011b) Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 30:632-643.
25. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, and Brundage BH (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334:296-302.
26. Becattini C, Manina G, Busti C, Gennarini S, and Agnelli G (2010) Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb Res 126:e51-56.
27. Beghetti M (2009) Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 7:225-233.
28. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, Ivy DD, Jais X, Schulze-Neick I, Galié N, et al. (2009) Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 68:948-955.
29. Beghetti M, Hoeper MM, Kiely DG, Carlsen J, Schwierin B, Segal ES, and Humbert M (2008) Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res 64:200-204.
30. Beghetti M, Reber G, de MP, Vadas L, Chiappe A, Spahr-Schopfer I, and Rimensberger PC (2002) Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur Respir J 19:518-524.
31. Benden C, Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, Dobbels F, Kirk R, Rahmel AO, Stehlik J, and Hertz MI (2011) The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Lung and Heart-Lung Transplantation Report-2011. J Heart Lung Transplant 30:1123-1132.
32. Benza R, Gupta H, Soto F, Park M, Torres F, Frey N, and Murali S (2010a) Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: the COMPASS-3 study (Abstract). Chest 138:840.
33. A. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, and McGoon MD (2012) An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL. Chest http://dx.doi.org/10.1378/chest.11-1460.
34. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. (2010b) Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122:164-172.
35. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, and Rubin LJ (2011) Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant 30:1327-1333.
36. Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, and Watson HR (1998) Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol. 37:952-960.
37. Bourge R, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro SM, Rubin LJ, McSwain CS, Gotzkowsky SK, et al. (2010) Transitioning patients from inhaled iloprost to inhaled treprostinil sodium: an interim analysis (Abstract). Am J Respir Crit Care Med 181:A3342.
38. Boutet K, Montani D, Jaïs X, Yaïci A, Sitbon O, Simonneau G, and Humbert M (2008) Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2:249-265.
39. Breccia M and Alimena G (2010) Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk Res 34:129-134.
40. Burgess G, Hoogkamer H, Collings L, and Dingemanse J (2008) Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 64:43-50.
41. Chakinala M (2009) Evaluating recent therapeutic trials in pulmonary arterial hypertension: raising the bar for clinical investigation. Adv Pulm Hypertens 8: 25-31.
42. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, et al. (2001) Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119-1123.
43. Chen H, Shiboski SC, Golden JA, Gould MK, Hays SR, Hoopes CW, and De Marco T (2009) Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension. Am J Respir Crit Care Med 180:468-474.
44. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, Rahmel AO, Stehlik J, and Hertz MI (2011) The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant 30:1104-1122.
45. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, and Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70-75.
46. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, and Kinsella JP (2000) Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 342:469-474.
47. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, and Tinker A (2002) Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 26:194-201.
48. Corbin JD, Beasley A, Blount MA, and Francis SH (2005) High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 334:930-938.
49. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, and Kernis JT (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349.
50. Dahal BK, Heuchel R, Pullamsetti SS, Wilhelm J, Ghofrani HA, Weissmann N, Seeger W, Grimminger F, and Schermuly RT (2011) Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β. Pulm Circ 1:259-268.
51. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, and Chang CT (1998) Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 101:325-334.
52. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, and Wharton J (2002) ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165:398-405.
53. de Kogel CE and Schellens JH (2007) Imatinib. Oncologist 12:1390-1394.
54. de Perrot M, Granton JT, McRae K, Pierre AF, Singer LG, Waddell TK, and Keshavjee S (2012) Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. J Thorac Cardiovasc Surg 143:910-918.
55. Dhalla IA, Juurlink DN, Gomes T, Granton JT, Zheng H, and Mamdani MM (2012) Selective serotonin reuptake inhibitors and pulmonary arterial hypertension: a case-control study. Chest 141:348-353.
56. Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, Thum T, Wort SJ, Bédard E, Gibbs JS, Bauersachs J, et al. (2008) Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 117:3020-3030.
57. Dingemanse J, van Giersbergen PL, Patat A, and Nilsson PN (2010) Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther 15:157-163.
58. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL, and Scientific Leadership Council of the Pulmonary Hypertension Association (2008) Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 160:5-9.
59. Duggan N, Bonneau O, Hussey M, Quinn DA, Manley P, Walker C, Westwick J, and Thomas MJ (2010) Comparison of effects of imatinib and nilotinib in a rodent model of pulmonary arterial hypertension (Abstract). Am J Respir Crit Care Med 181:A6304.
60. Dumitrascu R, Kulcke C, Königshoff M, Kouri F, Yang X, Morrell N, Ghofrani HA, Weissmann N, Reiter R, Seeger W, et al. (2011) Terguride ameliorates monocrotaline- induced pulmonary hypertension in rats. Eur Respir J 37:1104-1118.
61. Dunn ME, Althof SE, and Perelman MA (2007) Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 19:119-123.
62. Enright PL (2003) The six-minute walk test. Respir Care 48:783-785.
63. Fadini GP, Avogaro A, Ferraccioli G, and Agostini C (2010) Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. Eur Respir J 35:418-425.
64. Ergonex Pharma GmbH (2008) Ergonex Pharma initiates phase II clinical trial of Terguride in pulmonary arterial hypertension, 2008 Jan 29. Available at: http://www.ergonex.com/attachments/news/26/Media_Release_final_V2.pdf.
65. Eriksson C, Gustavsson A, Kronvall T, and Tysk C (2011) Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis 20:77-80.
66. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231.
67. Fernandes JL, Sampaio RO, Brandão CM, Accorsi TA, Cardoso LF, Spina GS, Tarasoutchi F, Pomerantzeff P, Auler JO Jr., and Grinberg M (2011) Comparison of inhaled nitric oxide versus oxygen on hemodynamics in patients with mitral stenosis and severe pulmonary hypertension after mitral valve surgery. Am J Cardiol 107:1040-1045.
68. Ferrantino M and White RJ (2011) Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 12:2583-2593.
69. Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, and Wessel DL (2011) Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med 37:502-509.
70. Frampton JE (2011) Ambrisentan. Am J Cardiovasc Drugs 11:215-226.
71. Francis SH, Busch JL, Corbin JD, and Sibley D (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62:525-563.
72. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, and Kneussl M (1997) The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112:714-721.
73. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, et al. (2011) The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 139:128-137.
74. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, and Nishikibe M (1994) Clearance of circulating endothelin-1 by ETB receptor in rats. Biochem Biophys Res Commun 199:1461-1465.
75. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, and Frye RL (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70:580-587.
76. Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut SM, and Halpern SD (2012) Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 141:20-26.
77. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, et al. (2005a) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46:529-535.
78. Galié N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M, and Bosentan Randomized Trial of Endothelin Antagonist Therapy- 5 (BREATHE-5) Investigators (2006) Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114:48-54.
79. Galié N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, et al. (2009a) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894-2903.
80. Galié N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. (2005b) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157.
81. Galié N, Hoeper MM, Gibbs JS, and Simonneau G (2011) Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J 37:475-476.
82. Galié N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. (2009b) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493-2537.
83. Galié N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, et al. (2002) Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496-1502.
84. Galié N, Negro L, and Simonneau G (2009c) The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev 18:148-153.
85. Galié N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, et al. (2008a) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117:3010-3019.
86. Galié N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, and Simonneau G (2008b) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371:2093-2100.
87. García Hernández FJ, Castillo Palma MJ, González León R, Garrido Rasco R, Ocaña Medina C, and Sánchez Román J (2008) [Experience with imatinib to treat pulmonary arterial hypertension]. Arch Bronconeumol 44:689-691.
88. Garin MC, Clark L, Chumney EC, Simpson KN, and Highland KB (2009) Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig 29:635-646.
89. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, Ewert R, Weimann G, and Grimminger F (2010a) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 36:792-799.
90. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al. (2010b) Imatinib in pulmonary arterial hypertension in patients with inadequate response to established therapy. Am J Respir Crit Care Med 182:1171-1177.
91. Ghofrani HA, Seeger W, and Grimminger F (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353:1412-1413.
92. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, and Stewart DJ (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732-1739.
93. Giaid A and Saleh D (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333:214-221.
94. Goldstein BS, Sweet SC, Mao J, Huddleston CB, and Grady RM (2011) Lung transplantation in children with idiopathic pulmonary arterial hypertension: an 18-year experience. J Heart Lung Transplant 30:1148-1152.
95. Gomberg-Maitland M, Dufton C, Oudiz RJ, and Benza RL (2011) Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol 57:1053-1061.
96. Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, and Barst RJ (2005) Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172:1586-1589.
97. Gorkin L, Hvidsten K, Sobel RE, and Siegel R (2006) Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 60:500-503.
98. Gresele P, Momi S, and Falcinelli E (2011) Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 72:634-646.
99. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, Weissmann N, Mück W, Unger S, Wensing G, et al. (2009) First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 33:785-792.
100. Gruenig E, Michelakis E, Vachiéry JL, Vizza CD, Meyer FJ, Doelberg M, Bach D, Dingemanse J, and Galié N (2009) Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 49: 1343-1352.
101. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, and Eddahibi S (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111: 2812-2819.
102. Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54:S10-19.
103. Hervé P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, and Drouet L (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99:249-254.
104. Higenbottam T, Butt AY, McMahon A, Westerbeck R, and Sharples L (1998) Longterm intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80:151-155.
105. Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, et al. (2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 29:137-149.
106. Hislop AA, Moledina S, Foster H, Schulze-Neick I, and Haworth SG (2011) Longterm efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 38:70-77.
107. Hoeper M, Barst RJ, Galié N, Hassoun P, Morrell N, Peacock A, Simonneau G, Tapson V, Torres F, Lu K, Quinn D, and Ghofrani HA (2011) Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) (Abstract no. 413), in Annual Congress of the European Respiratory Society; 2011 Sep 25; Amsterdam, The Netherlands. p 50S. European Respiratory Society, Sheffield, UK.
108. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, and Niedermeyer J (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26:858-863.
109. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, and Torbicki A (2004) End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 43:48S-55S.
110. Humbert M, Barst RJ, Robbins IM, Channick RN, Galié N, Boonstra A, Rubin LJ, Horn EM, Manes A, and Simonneau G (2004) Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 24:353-359.
111. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023-1030.
112. Ichinose F, Roberts JD Jr., and Zapol WM (2004) Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 109: 3106-3111.
113. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, et al. (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327: 736-745.
114. Ivy DD, Calderbank M, Wagner BD, Dolan S, Nyquist AC, Wade M, Nickels WM, and Doran AK (2009) Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol 30:823-829.
115. Ivy DD, Claussen L, and Doran A (2007) Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 99:696-698.
116. Ivy DD, Doran AK, Smith KJ, Mallory GB Jr., Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, and Abman SH (2008) Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51:161-169.
117. Ivy DD, Rosenzweig EB, Lemarié JC, Brand M, Rosenberg D, and Barst RJ (2010) Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 106:1332-1338.
118. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, et al. (2008) Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 52:2127-2134.
119. Jin H, Yang RH, and Oparil S (1992) Cicletanine blunts the pulmonary pressor response to acute hypoxia in rats. Am J Med Sci 304:14-19.
120. Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Le T, Lee P, Seary ME, Hawker GA, and Feldman BM (2012) Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 39:276-285.
121. Johnson SR, Mehta S, and Granton JT (2006) Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 28:999-1004.
122. Jones DA, Benjamin CW, and Linseman DA (1995) Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 48:890-896.
123. Kalinowski L, Dobrucki IT, and Malinski T (2001) Cicletanine stimulates nitric oxide release and scavenges superoxide in endothelial cells. J Cardiovasc Pharmacol 37:713-724.
124. Kallen AJ, Lederman E, Balaji A, Trevino I, Petersen EE, Shoulson R, Saiman L, Horn EM, Gomberg-Maitland M, Barst RJ, et al. (2008) Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 29:342-349.
125. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, and McGoon MD (2011) Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest 139: 1285-1293.
126. Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Widlitz AC, Rosenzweig EB, and Barst RJ (2006) Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 19:370-374.
127. Kedzierski RM and Yanagisawa M (2001) Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41:851-876.
128. Kekewska A, Görnemann T, Jantschak F, Glusa E, and Pertz HH (2012) Antiserotonergic properties of terguride in blood vessels, platelets and valvular interstitial cells. J Pharmacol Exp Ther 340:369-376.
129. Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, and Sitbon O (2012) Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 31:150-158.
130. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, and Barst RJ (1995) Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 91:2028-2035.
131. Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, et al. (2008) Combined tyrosine and serine/ threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118:2081-2090.
132. Krauth MT, Binder T, Ohler L, Jäger U, and Valent P (2008) Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. Leuk Res 32:1779-1783.
133. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K, and Kuwabara K (2007) 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 322:1181-1188.
134. Laliberte K, Arneson C, Jeffs R, Hunt T, and Wade M (2004) Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 44:209-214.
135. Lammers AE, Hislop AA, Flynn Y, and Haworth SG (2007) Epoprostenol treatment in children with severe pulmonary hypertension. Heart 93:739-743.
136. Lane CR and Trow TK (2011) Pregnancy and pulmonary hypertension. Clin Chest Med 32:165-174.
137. Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, and Vachiery JL (2006) Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129:1636-1643.
138. Launay JM, Hervé P, Callebert J, Mallat Z, Collet C, Doly S, Belmer A, Diaz SL, Hatia S, Côté F, et al. (2012) Serotonin 5-HT2B receptors are required for bonemarrow contribution to pulmonary arterial hypertension. Blood 119:1772-1780.
139. Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129-1135.
140. Lederer DJ, Horn EM, Rosenzweig EB, Karmally W, Jahnes M, Barst RJ, and Kawut SM (2008) Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulm Pharmacol Ther 21:112-114.
141. Lee WT, Kirkham N, Johnson MK, Lordan JL, Fisher AJ, and Peacock AJ (2011) Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension. Eur Respir J 37:472-474.
142. Letairis [U.S. package insert]. (2011) Gilead Sciences, Inc., Foster City, CA. Levin ER (1995) Endothelins. N Engl J Med 333:356-363.
143. Levy M, Celermajer DS, Bourges-Petit E, Del Cerro MJ, Bajolle F, and Bonnet D (2011) Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 158:584-588.
144. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, et al. (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 118:855-864.
145. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J, Colston J, Loughlin L, Nilsen M, Dempsie Y, et al. (2004) Overexpression of the 5-hydroxytryptamin transporter gene: effect on pulmonary hemodynamics and hypoxiainduced pulmonary hypertension. Circulation 109:2150-2155.
146. MacLean MR, Herve P, Eddahibi S, and Adnot S (2000) 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131:161-168.
147. Macrae DJ, Field D, Mercier JC, Møller J, Stiris T, Biban P, Cornick P, Goldman A, Göthberg S, Gustafsson LE, et al. (2004) Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med 30:372-380.
148. Maiya S, Hislop AA, Flynn Y, and Haworth SG (2006) Response to bosentan in children with pulmonary hypertension. Heart 92:664-670.
149. Massachusetts Executive Office of Health and Human Services (2011) Table 43: pulmonary arterial hypertension agents. Available at https://masshealthdruglist.ehs.state.ma.us/MHDL/pubtheradetail.do?id_43.
150. Matamis D, Pampori S, Papathanasiou A, Papakonstantinou P, Tsagourias M, Galiatsou E, Koulouras V, and Nakos G (2012) Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics. Circ Heart Fail 5:47-53.
151. Mathier MA, McDevitt S, and Saggar R (2010) Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations. J Heart Lung Transplant 29:1210-1217.
152. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, et al. (2009) Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 135:122-129.
153. McGoon MD and Kane GC (2009) Pulmonary hypertension: diagnosis and management. Mayo Clin Proc 84:191-207.
154. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al. (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573-1619.
155. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, and Seeger W (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55:1915-1922.
156. McLaughlin VV, Davis M, and Cornwell W (2011) Pulmonary arterial hypertension. Curr Probl Cardiol 36:461-517.
157. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, Robbins IM, Tapson VF, McGoon MD, Badesch DB, et al. (2003) Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension. J Cardiovasc Pharmacol 41:293-299.
158. McLaughlin VV, Shillington A, and Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106:1477-1482.
159. Melnick L, Barst RJ, Rowan CA, Kerstein D, and Rosenzweig EB (2010) Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension. Am J Cardiol 105:1485-1489.
160. Melot C, Hallemans R, Naeije R, Mols P, and Lejeune P (1984) Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 130:612-616.
161. Minai OA, Chaouat A, and Adnot S (2010) Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 137:39S-51S.
162. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, Kern A, Knorr A, Lang D, Muenter K, et al. (2009) Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4:853-865.
163. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, and Miyatake K (2000) Clinical correlates and prognostic significance of sixminute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487-492.
164. Mulligan C and Beghetti M (2011) Inhaled iloprost for the control of acute pulmonary hypertension in children: A systematic review. Pediatr Crit Care Med http://dx.doi.org/10.1097/PCC.0b013e31822f192b.
165. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-Shiba M, Okumura H, Tabata Y, et al. (2003) Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108:889-895.
166. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, and Kass DA (2009) Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with preexisting advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53:207-215.
167. Napoli C and Ignarro LJ (2003) Nitric oxide-releasing drugs. Annu Rev Pharmacol Toxicol 43:97-123.
168. Narumiya S, Sugimoto Y, and Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79:1193-1226.
169. Neonatal Inhaled Nitric Oxide Study Group (1997) Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 336:597-604.
170. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, and Millan MJ (2002a) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 303:805-814.
171. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N, and Millan MJ (2002b) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303:815-822.
172. Okano Y, Yoshioka T, Shimouchi A, Satoh T, and Kunieda T (1997) Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 349:1365.
173. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, and Seeger W (2004) Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 102:139-153.
174. Olschewski H, Simonneau G, Galié N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al. (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322-329.
175. Opitz CF, Ewert R, Kirch W, and Pittrow D (2008) Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 29:1936-1948.
176. Oudiz RJ, Galié N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, et al. (2009) Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 54:1971-1981.
177. Oudiz R, Shapiro S, Torres F, Feldman J, Frost A, Allard M, Blair C, and Gillies H (2011) ATHENA-1: Hemodynamic improvements following the addition of ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension (Abstract). Chest 140:905A.
178. Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, Smit EF, and Vonk- Noordegraaf A (2008) Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 32:232-235.
179. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, and Rubenfire M (2001) Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 17:647-652.
180. Packer M, Medina N, Yushak M, and Wiener I (1984) Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J 52:106-111.
181. Patterson KC, Weissmann A, Ahmadi T, and Farber HW (2006) Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 145:152-153.
182. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, and Stewart S (2007) An epidemiological study of pulmonary arterial hypertension. Eur Respir J 30:104-109.
183. Perros F, Montani D, Dorfmüller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, et al. (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Resp Crit Care Med 178:81-88.
184. Pfizer Direct Healthcare Professional Communication (2011) Increased risk of mortality in paediatric patients with pulmonary arterial hypertension with the use of higher than recommended doses of Revatio (sildenafil citrate). Pfizer, Inc., New York, NY. Available at http://www.imb.ie/images/uploaded/documents/Pfizer%20Revatio%20DHPC%2004.09.11.pdf.
185. Porvasnik SL, Germain S, Embury J, Gannon KS, Jacques V, Murray J, Byrne BJ, Shacham S, and Al-Mousily F (2010) PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther 334: 364-372.
186. Provencher S and Sitbon O (2009) Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence. Eur Respir J 34:7-9.
187. Rabinovitch M (2007) Pathobiology of pulmonary hypertension. Annu Rev Pathol 2:369-399.
188. Red Book 2010, 114th ed. PDR Network, LLC, Montvale, NJ. Revatio [U.S. package insert]. (2005) Pfizer, Inc., New York, NY.
189. Revatio [Summary of Product Characteristics] (2012). European Medicines Agency. London, UK. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000638/WC500055840.pdf.
190. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, and Koerner SK (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:216-223.
191. Rich JD, Glassner C, Wade M, Coslet S, Arneson C, Doran A, and Gomberg-Maitland M (2012) The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest 141:36-42.
192. Riechers H, Albrecht HP, Amberg W, Baumann E, Bernard H, Böhm HJ, Klinge D, Kling A, Müller S, Raschack M, et al. (1996) Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem. 39:2123-2128.
193. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, and Barst RJ (2005) Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46:697-704.
194. Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shaughnessy RD, Channick RN, Auger WR, Fedullo PF, Smith CM, Kriett JM, et al. (1999) Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 84:682-686.
195. Rubenfire M, McLaughlin VV, Allen RP, Elliott G, Park MH, Wade M, and Schilz R (2007) Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 132:757-763.
196. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, and Hoeffken G (2001) Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120:1562-1569.
197. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903.
198. Rubin LJ, Badesch DB, Fleming TR, Galié N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, et al. (2011a) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140:1274-1283.
199. Rubin L, Parikh K, Pulido T, Jerjes-Sanchez C, Allen R, White J, Torbicki A, Xu K, Yehle D, Laliberte K, et al. (2011b) FREEDOM-M: Efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension (Abstract). Chest 140:1044A.
200. Saji T, Ozawa Y, Ishikita T, Matsuura H, and Matsuo N (1996) Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 78:244-247.
201. Sandoval J, Gaspar J, Peña H, Santos LE, Córdova J, del Valle K, Rodríguez A, and Pulido T (2011) Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J 38:1343-1348.
202. Sandoval J, Torbicki A, Souza R, Ramírez A, Kurzyna M, Jardim C, Jerjes-Sánchez Díaz C, Teal SA, Hwang LJ, Pulido T, et al. (2012) Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther 25:33-39.
203. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 115:2811-2821.
204. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlüter KD, Dingendorf A, Hackemack S, Kolosionek E, Kaulen C, et al. (2008) Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 32:881-891.
205. Schmid ER, Bürki C, Engel MH, Schmidlin D, Tornic M, and Seifert B (1999) Inhaled nitric oxide versus intravenous vasodilators in severe pulmonary hypertension after cardiac surgery. Anesth Analg 89:1108-1115.
206. Schrör K and Weber AA (1997) Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl 48:63-91.
207. Shah SJ, Gomberg-Maitland M, Thenappan T, and Rich S (2009) Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 136:694-700.
208. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, Mandayam S, Ginzton LE, and Brundage BH (1997) Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30:343-349.
209. Sidharta PN, van Giersbergen PL, Halabi A, and Dingemanse J (2011) Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 67:977-984.
210. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, et al. (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800-804.
211. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43-S54.
212. Simonneau G, Rubin LJ, Galié N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, et al. (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149:521-530.
213. Simonneau G, Torbicki A, Hoeper M, Delcroix M, Karlócai K, Galié N, Degano B, Bonderman D, Kurzyna M, Efficace M, et al. (2012) Selexipag, on oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J http://dx.doi.org/10.1183/09031936.00137511.
214. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, and Simonneau G (2004) Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Resp Crit Care Med 170:1212-1217.
215. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, and Simonneau G (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40: 780-788.
216. Skoro-Sajer N, Lang IM, Harja E, Kneussl MP, Sing WG, and Gibbs SJ (2008) A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension. Clin Pharmacokinet 47:611-618.
217. Smadja DM, Mauge L, Gaussem P, d'Audigier C, Israel-Biet D, Celermajer DS, Bonnet D, and Lévy M (2011) Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis 14:17-27.
218. Smyth EM, Grosser T, Wang M, Yu Y, and FitzGerald GA (2009) Prostanoids in health and disease. J Lipid Res 50:S423-S428.
219. Souza R, Sitbon O, Parent F, Simonneau G, and Humbert M (2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax 61:736.
220. Spence R, Mandagere A, Dufton C, and Venitz J (2008) Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol 48:1451-1459.
221. Spence R, Mandagere A, Harrison B, Dufton C, and Boinpally R (2009) No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci 98:4962-4974.
222. Steinhorn RH (2008) Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. J Perinatol 28:S67-S71.
223. Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Dilleen M, Oakes M, and Wessel DL (2009) Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 155:841-847.
224. Stewart DJ, Levy RD, Cernacek P, and Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114:464-469.
225. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, and Shekerdemian LS (2003) Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 29:1996-2003.
226. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, and Tamm M (2008) A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32:619-628.
227. Strange G, Keogh A, Dalton B, and Gabbay E (2011) Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. Expert Rev Pharmacoecon Outcomes Res 11:253-263.
228. Takahashi M, Nakamura T, Toba T, Kajiwara N, Kato H, and Shimizu Y (2004) Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng 10:771-779.
229. Takatsuki S, Calderbank M, and Ivy DD (2012) Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol http://dx.doi.org/10.1007/s00246-012-0180-4.
230. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Branzi A, and Galié N (2005) Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100:131-138.
231. Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A, and Barst RJ (2006) Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129:683-688.
232. Tapson VF, Torres F, Kermeen F, Keogh A, Allen RP, Frantz R, Badesch DB, Frost AE, Shapiro S, Sigman J, et al. (2009) Results of the FREEDOM-C study: a pivotal study of oral treprostinil used adjunctively with an ERA and/or PDE5-inhibitor for the treatment of PAH (Abstract). Am J Respir Crit Care Med 179:A1040.
233. ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, and Rosenkranz S (2009) Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 98: 265-267.
234. Thenappan T, Glassner C, and Gomberg-Maitland M (2012) Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest 141:642-650.
235. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, and Gomberg-Maitland M (2010) Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 35:1079-1087.
236. Tournier A, Wahl D, Chaouat A, Max JP, Regnault V, Lecompte T, and Chabot F (2010) Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. Thromb Res 12:e418-422.
237. Tracleer [U.S. package insert]. (2011) Actelion Pharmaceuticals US, Inc., South San Francisco, CA.
238. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, and Voelkel NF (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925-1932.
239. Ulrich S, Huber LC, Fischler M, Treder U, Maggiorini M, Eberli FR, and Speich R (2011) Platelet serotonin content and transpulmonary platelet serotonin gradient in patients with pulmonary hypertension. Respiration 81:211-216.
240. United States Food and Drug Administration (2001) Cardiovascular and Renal Drugs Advisory Committee. United Therapeutics Corporation Presentation: Efficacy of treprostinil. August 9-10, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/slides/3775s1.htm.
241. United States Food and Drug Administration (2010) FDA Advisory Committee Briefing Document, Cardiovascular and Renal Drugs Advisory Committee, Center for Drug Evaluation and Research, 2010 Jul 29. Available at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm220249.htm.
242. United Therapeutics (2008) Freedom-C trial of oral treprostinil in pulmonary arterial hypertension fails to meet primary endpoint, 2008 Nov 17. Available at http://ir.unither.com/releasedetail.cfm?ReleaseID_347887.
243. United Therapeutics (2009) 2009 Annual Report. United Therapeutics, Silver Spring, MD. Available at http://ir.unither.com/annuals.cfm.
244. United Therapeutics (2011a) FREEDOM-C(2) trial of oral treprostinil in pulmonary arterial hypertension does not meet primary endpoint, 2011 Aug 24. Available at http://ir.unither.com/releasedetail.cfm?ReleaseID_600804.
245. United Therapeutics (2011b) FREEDOM-M trial of oral treprostinil in pulmonary arterial hypertension meets primary endpoint, 2011 Jun 6. Available at http://ir.unither.com/releasedetail.cfm?ReleaseID_582786.
246. United Therapeutics (2012) Oral treprostinil new drug application accepted by FDA for review, 2012 Feb 21. Available at http://ir.unither.com/releasedetail.cfm?ReleaseID_650003.
247. Vachiery JL, Huez S, Gillies H, Layton G, Hayashi N, Gao X, and Naeije R (2011) Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol 71:289-292.
248. Valerio G, Bracciale P, and Grazia D'Agostino A (2009) Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 3:15-21.
249. van Giersbergen PL, Halabi A, and Dingemanse J (2006) Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 44:113-118.
250. Vargas-Origel A, Gómez-Rodríguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcón-Santos SB, and Amador-Licona N (2010) The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol 27:225-230.
251. Venitz J, Zack J, Gillies H, Allard M, Regnault J, and Dufton C (2011) Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol http://dx.doi.org/10.1177/0091270011423662.
252. Ventavis [U.S. package insert]. (2011) Actelion Pharmaceuticals US, Inc., South San Francisco, CA.
253. Walkey AJ, Fein D, Horbowicz KJ, and Farber HW (2011) Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Pulm Pharmacol Ther 24:421-425.
254. Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, Zhu JH, and Chen JZ (2007) Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 49:1566-1571.
255. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, and Griffin JD (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94:1765-1769.
256. Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, and Wilkins MR (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172:105-113.
257. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, Westwood MA, Stefanidis A, Ng LL, Pennell DJ, et al. (2005) Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 171:1292-1297.
258. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, and Mitchell MI (2008) Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 48:610-618.
259. Xie YP, Chen B, Sanders P, Guo A, Li Y, Zimmerman K, Wang LC, Weiss RM, Grumbach IM, Anderson ME, et al. (2012) Sildenafil prevents and reverses transverse- tubule remodeling and Ca2 handling dysfunction in right ventricle failure induced by pulmonary artery hypertension. Hypertension 59:355-362.
260. Yang J, Li X, Al-Lamki RS, Southwood M, Zhao J, Lever AM, Grimminger F, Schermuly RT, and Morrell NW (2010) Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res 107:252-262.
261. Yip HK, Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, Wu CJ, and Fu M (2008) Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Crit Care Med 36:873-880.
262. Young TE, Lundquist LJ, Chesler E, and Weir EK (1983) Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension. Am J Cardiol 51:195-200.
263. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, and Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660-665.
264. Zacà V, Metra M, Danesi R, Lombardi C, Verzura G, and Dei Cas L (2009) Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Ther Adv Respir Dis 3:11-14.
265. Zhang M, Takimoto E, Hsu S, Lee DI, Nagayama T, Danner T, Koitabashi N, Barth AS, Bedja D, Gabrielson KL, et al. (2010) Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol 56:2021-2030.
266. Zopf DA, das Neves LA, Nikula KJ, Huang J, Senese PB, and Gralinski MR (2011) C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotalineinduced pulmonary arterial hypertension in rats. Eur J Pharmacol 670:195-203.